MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells

• Published in: Carcinogenesis (New York) Vol. 27; no. 4; pp. 874 - 881
• Main Authors: Moneypenny, Craig G., Shao, Jing, Song, Yanyu, Gallagher, Evan P.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.04.2006; Oxford Publishing Limited (England)
• Subjects: 4-HNE; 4-hydroxynonenal; acute lymphoblastic leukemia; acute myelogenous leukemia; ALL; AML; Antineoplastic Agents, Phytogenic - pharmacology; Biological and medical sciences; Carcinogenesis, carcinogens and anticarcinogens; Cell Culture Techniques; Cell Cycle - drug effects; Cell Survival - drug effects; DNA Damage; DNA topoisomerase II; Dose-Response Relationship, Drug; Etoposide - pharmacology; Female; Fetus; FISH; fluorescence in situ hybridization; Gene Rearrangement - drug effects; hematopoietic stem cells; Hematopoietic Stem Cells - drug effects; Histone-Lysine N-Methyltransferase; HSC; Humans; IAL; infant acute leukemia; kDNA; kinetoplast DNA; Leukemia - chemically induced; Maternal-Fetal Exchange; Medical sciences; mixed lineage leukemia; MLL; MoAB; monoclonal antibody; Myeloid-Lymphoid Leukemia Protein - genetics; Phycoerythrin; Pregnancy; topo II; Tumors; Antineoplastic agent; Human; DNA topoisomerase (ATP-hydrolysing); Enzyme; Stem cell; Low dose; Enzyme inhibitor; Hematopoietic cell; Etoposide; Podophyllotoxine derivatives; Isomerases; Fetal cell; Gene rearrangement; Antimitotic

During fetal development, the liver serves as the primary hematopoietic organ in which hematopoietic stem cells (HSC) comprise a large proportion of hepatic cell populations. Because HSC are capable of initiating long-term hematopoiesis, injury to these cells during pregnancy may play a role in the...